Antiangiogenetic agents [5–9] along with mTOR inhibitors [10, 11] or their combination [12] and immune checkpoint inhibitors [13], led to the regulatory approval of 10 different agents for metastatic RCC patients the last 12 years resulting in a significant increase of overall survival of RCC patients [14, 15]. Here, MTOR is linked to renal cell carcinoma.